Using EEG-based biomarker, high accuracy of predicting the likelihood of being CT+ was obtained, with high NPV and sensitivity to any traumatic bleeding and to hematomas. Specificity was significantly higher than standard CT decision rules.
Here are some articles published about BrainScope, and its impact in our communities
JAMA Network Open has published "Validation of a Machine Learning Brain Electrical Activity-Based Index to Aid in Diagnosing Concussion Among Athletes," a ground-breaking study on the accuracy of the BrainScope FDA-cleared biomarker, the Concussion Index, to indicate the likelihood and severity of concussive brain injury and to aid in evaluating an athlete's readiness to return to play.
BrainScope, a medical neurotechnology company that is a pioneer in the use of A.I. and machine learning in the creation of biomarkers of brain injuries and disease, was selected from five finalists as the company with the most commercial potential at the 5th Annual BioHealth Capital Region Crab Trap Competition
Check our video library to learn more about our technology and history.
Click here for a complete list of indications